Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kluger, H. M.
Right arrow Articles by Rimm, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kluger, H. M.
Right arrow Articles by Rimm, D. L.
Clinical Cancer Research Vol. 10, 173-177, January 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

Macrophage Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis

Harriet M. Kluger1, Marisa Dolled-Filhart23, Sofya Rodov1, Barry M. Kacinski4, Robert L. Camp2 and David L. Rimm2

1Departments of Medicine,2 Pathology,3 Genetics, and4 Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut

Purpose: Macrophage colony-stimulating factor-1 receptor (CSF-1R) is a transmembrane tyrosine kinase receptor, which is abnormally expressed in invasive breast cancer. Small cohort studies have demonstrated that increased expression of CSF-1R is associated with ipsilateral breast cancer recurrence. Correlation with survival has not been reported. Our aim was to further evaluate the role of CSF-1R in breast cancer, by studying the expression of CSF-1R in a large cohort of clinical specimens.

Experimental Design: Tissue microarrays containing 301 node-negative and 280 node-positive cases were used. Immunohistochemical staining was performed and correlated with overall survival, nodal status, and other clinicopathological data.

Results: CSF-1R expression was strongly associated with nodal status. Of the node-negative cases, 114 (38.9%) stained positive for CSF-1R, whereas 189 (67.5%) of the node-positive cases expressed CSF-1R (P < 0.0001). CSF-1R expression is also associated with larger tumor size (P = 0.02). Positive staining was strongly associated with decreased survival (P = 0.0003). Among node-negative patients, CSF-1R expression was associated with decreased overall survival (P = 0.045), whereas among node-positive patients, it was not (P = 0.47). In multivariate analysis, CSF-1R was not independent of nodal status as a predictor of survival.

Conclusions: CSF-1R expression is a strong predictor of poor outcome in nonmetastatic breast cancer. It is significantly more frequently expressed in patients with nodal involvement. Among the node-negative patients, it has a stronger association with survival than among the node-positive patients. Our findings support other preclinical findings that CSF-1R may be involved in local invasion and metastasis. Thus, this receptor may be an effective target for therapeutic agents.




This article has been cited by other articles:


Home page
Cancer Res.Home page
K. D. Bromberg, H. M. Kluger, A. Delaunay, S. Abbas, K. A. DiVito, S. Krajewski, and Z. Ronai
Increased Expression of the E3 Ubiquitin Ligase RNF5 Is Associated with Decreased Survival in Breast Cancer
Cancer Res., September 1, 2007; 67(17): 8172 - 8179.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. Schubert, C. Schalk-Hihi, G. T. Struble, H.-C. Ma, I. P. Petrounia, B. Brandt, I. C. Deckman, R. J. Patch, M. R. Player, J. C. Spurlino, et al.
Crystal Structure of the Tyrosine Kinase Domain of Colony-stimulating Factor-1 Receptor (cFMS) in Complex with Two Inhibitors
J. Biol. Chem., February 9, 2007; 282(6): 4094 - 4101.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Dolled-Filhart, L. Ryden, M. Cregger, K. Jirstrom, M. Harigopal, R. L. Camp, and D. L. Rimm
Classification of breast cancer using genetic algorithms and tissue microarrays.
Clin. Cancer Res., November 1, 2006; 12(21): 6459 - 6468.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
M. Dolled-Filhart, A. McCabe, J. Giltnane, M. Cregger, R. L. Camp, and D. L. Rimm
Quantitative In situ Analysis of {beta}-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome.
Cancer Res., May 15, 2006; 66(10): 5487 - 5494.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. M. McCarthy, M. Sznol, K. A. DiVito, R. L. Camp, D. L. Rimm, and H. M. Kluger
Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer
Clin. Cancer Res., July 15, 2005; 11(14): 5188 - 5194.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
H. M. Kluger, D. Chelouche Lev, Y. Kluger, M. M. McCarthy, G. Kiriakova, R. L. Camp, D. L. Rimm, and J. E. Price
Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease
Cancer Res., July 1, 2005; 65(13): 5578 - 5587.
[Abstract] [Full Text] [PDF]


Home page
Endocr Relat CancerHome page
N Normanno, A De Luca, D Aldinucci, M R Maiello, M Mancino, A D'Antonio, R De Filippi, and A Pinto
Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis
Endocr. Relat. Cancer, June 1, 2005; 12(2): 471 - 482.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. Harigopal, A. J. Berger, R. L. Camp, D. L. Rimm, and H. M. Kluger
Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer
Clin. Cancer Res., June 1, 2005; 11(11): 4083 - 4089.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
G. J. Vanasse, R. K. Winn, S. Rodov, A. W. Zieske, J. T. Li, J. C. Tupper, J. Tang, E. W. Raines, M. A. Peters, K. Y. Yeung, et al.
Bcl-2 Overexpression Leads to Increases in Suppressor of Cytokine Signaling-3 Expression in B Cells and De novo Follicular Lymphoma
Mol. Cancer Res., November 1, 2004; 2(11): 620 - 631.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Aharinejad, P. Paulus, M. Sioud, M. Hofmann, K. Zins, R. Schafer, E. R. Stanley, and D. Abraham
Colony-Stimulating Factor-1 Blockade by Antisense Oligonucleotides and Small Interfering RNAs Suppresses Growth of Human Mammary Tumor Xenografts in Mice
Cancer Res., August 1, 2004; 64(15): 5378 - 5384.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.